Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

CANbridge Approved to Launch Pruritus Therapy for Alagille Syndrome in China

publication date: Jun 2, 2023

Beijing CANbridge Pharma was approved to launch Maralixibat Chloride Oral Solution (Livmarli®) in China to treat cholestatic pruritus in patients at least one year old with Alagille syndrome. Livmarli (maralixibat) inhibits ileal bile acid transporters (IBAT), blocking bile circulation and lowering bile acid levels in the liver and serum. This reduces liver injury and relieves pruritus. Livmarli is the only medication approved in China, the US and EU to treat Alagille syndrome cholestatic pruritus. CANbridge, a rare disease company, acquired China rights for Livmarli from Mirum Pharma, a San Francisco-area biopharma. More details....

Stock Symbol: (HK: 1228)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here